Folate receptor alpha (FRα / FOLR1) tumor expression
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-FRA |
|---|---|
| Type | Biomarker |
| Aliases | FOLR1FRαFolate receptor 1Folate receptor alpha (FRα / FOLR1) expressionЕкспресія фолатного рецептора α (FRα / FOLR1) пухлиною |
| Status | reviewed 2026-04-27 |
| Diseases | None declared |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-MIRASOL-MOORE-2024 SRC-NCCN-OVARIAN-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC with VENTANA FOLR1 (FOLR1-2.1) RxDx Assay (companion diagnostic for mirvetuximab soravtansine); manual or auto-stain on FFPE. Unitscategorical: high (≥75% of viable tumor cells with ≥2+ membrane staining intensity) | medium (50-74% ≥2+) | low (25-49% ≥2+) | negative (<25% ≥2+) |
| Related biomarkers | None declared |
Notes
Companion diagnostic: VENTANA FOLR1 (FOLR1-2.1) RxDx Assay (Roche). Other FRα assays (Leica, custom) not validated for mirvetuximab selection. CSD-4 biomarker — newly added 2026-04 for ALGO-OVARIAN-2L.
Used By
Algorithms
ALGO-OVARIAN-2L- ALGO-OVARIAN-2L
Indications
IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB- IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB
Questionnaires
QUEST-OVARIAN-1L-STUB- Ovarian carcinoma — first line